Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.

Ruxolitinib is associated with reduced HCRU and direct costs of medical care in addition to increased survival, suggesting it to be a cost-effective advance for patients with MF.